*: statistically significant p < 0.05. CD39: cluster of differentiation 39 (ecto-adenosine triphosphate diphosphohydrolase); CD73: cluster of differentiation 73 (ecto-5’-nucleotidase).
Declarations
Author contributions
AGT, WE, and NNT: Conceptualization, Methodology, Writing—original draft, Writing—review & editing. YE: Conceptualization, Methodology, Writing—original draft, Writing—review & editing, Data curation, Formal analysis, Resources, Investigation,Visualization. All authors read and approved the submitted version.
Conflicts of interest
The authors declare no conflict of interest.
Ethical approval
Ethics approval was obtained from the Ethical Committee of Chest Hospital, Assiut, Egypt (08-2022-24). All procedures performed in studies involving human participants were in accordance with the ethical standards of national research committee and with the 2013 Helsinki Declaration.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent to publication
Not applicable.
Availability of data and materials
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Global Asthma Network. The Global Asthma Report 2018 [Internet].Auckland (NZ): Global Asthma Network; c2018 [cited 2026 Apr 20]. Available from: https://globalasthmareport.org/2018/index.html
Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults.Front Pediatr. 2019;7:246. [DOI] [PubMed] [PMC]
Le TT, Berg NK, Harting MT, Li X, Eltzschig HK, Yuan X. Purinergic Signaling in Pulmonary Inflammation.Front Immunol. 2019;10:1633. [DOI] [PubMed] [PMC]
Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC. CD39 and control of cellular immune responses.Purinergic Signal. 2007;3:171–80. [DOI] [PubMed] [PMC]
Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation.Trends Mol Med. 2013;19:355–67. [DOI] [PubMed] [PMC]
Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation.Nature. 2014;509:310–7. [DOI] [PubMed] [PMC]
Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Immunol Rev. 2017;276:121–44. [DOI] [PubMed] [PMC]
Hicks-Berger CA, Chadwick BP, Frischauf AM, Kirley TL. Expression and characterization of soluble and membrane-bound human nucleoside triphosphate diphosphohydrolase 6 (CD39L2).J Biol Chem. 2000;275:34041–5. [DOI] [PubMed]
Lee J, Park H, Moon S, Do JT, Hong K, Choi Y. Expression and Regulation of CD73 during the Estrous Cycle in Mouse Uterus.Int J Mol Sci. 2021;22:9403. [DOI] [PubMed] [PMC]
Wilfinger WW, Mackey K, Chomczynski P. Effect of pH and ionic strength on the spectrophotometric assessment of nucleic acid purity.Biotechniques. 1997;22:474–81. [DOI] [PubMed]
Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR.Genome Res. 1996;6:986–94. [DOI] [PubMed]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods. 2001;25:402–8. [DOI] [PubMed]
Mamun KZ, Mahboob N, Mamun KT, Iqbal H, S A. Immunological aspects of COVID-19: what we know so far.Bangla J Med. 2021;32:43–52. [DOI]
Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, Nakajima T, et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization.J Immunol. 1994;153:3574–83. [PubMed]
Wang L, Tang P, Shi C, Wan Y, Tang W, Hou X, et al. Expression of CD39 mRNA is altered in the peripheral blood of patients with allergic asthma.Biomed Rep. 2014;2:75–8. [DOI] [PubMed] [PMC]
Chen S, Wu S, Zhang L, Zhang W, Liu Y, Chen B, et al. CD39: the potential target in small cell lung cancer.Transl Lung Cancer Res. 2020;9:1483–95. [DOI] [PubMed] [PMC]
Wang LL, Tang HP, Shi GC, Wan HY, Tang W, Hou XX, et al. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.Mol Med Rep. 2013;8:1432–8. [DOI] [PubMed]
Yegutkin GG, Wieringa B, Robson SC, Jalkanen S. Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities.FASEB J. 2012;26:3875–83. [DOI] [PubMed] [PMC]
Huang YA, Chen JC, Wu CC, Hsu CW, Ko AM, Chen LC, et al. Reducing Lung ATP Levels and Alleviating Asthmatic Airway Inflammation through Adeno-Associated Viral Vector-Mediated CD39 Expression.Biomedicines. 2021;9:656. [DOI] [PubMed] [PMC]
Montaño LM, Vargas MH, Díaz-Hernández V, De Ita M, Kazakova R, Barajas-López C. Decreased expression of ectonucleotidase E-NPP1 in leukocytes from subjects with severe asthma exacerbation.Allergy. 2016;71:124–8. [DOI] [PubMed]
Jiang Y, Hu W, Cai Z, Lin C, Ye S. Peripheral Multiple Cytokine Profiles Identified CD39 as a Novel Biomarker for Diagnosis and Reflecting Disease Severity in Allergic Rhinitis Patients.Mediators Inflamm. 2023;2023:3217261. [DOI] [PubMed] [PMC]
Díaz-García E, García-Tovar S, Alfaro E, Zamarrón E, Mangas A, Galera R, et al. Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.Front Immunol. 2022;13:847894. [DOI] [PubMed] [PMC]
Hu XM, Shi NR, Zhang JZ, Zuo YQ, Wang X, Zhao YF, et al. CD73: Friend or Foe in Lung Injury.Int J Mol Sci. 2023;24:5545. [DOI] [PubMed] [PMC]
Caiazzo E, Cerqua I, Riemma MA, Turiello R, Ialenti A, Schrader J, et al. Allergic sensitization is oriented by CD73 enzyme.Eur Respir J Open Res. 2019;5:PP213. [DOI]
Garcia-Garcia L, Olle L, Martin M, Roca-Ferrer J, Muñoz-Cano R. Adenosine Signaling in Mast Cells and Allergic Diseases.Int J Mol Sci. 2021;22:5203. [DOI] [PubMed] [PMC]
Tian Z, Dixon J, Guo X, Deal B, Liao Q, Zhou Y, et al. Co-inhibition of CD73 and ADORA2B Improves Long-Term Cigarette Smoke Induced Lung Injury.Front Physiol. 2021;12:614330. [DOI] [PubMed] [PMC]
Cronstein BN, Sitkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.Nat Rev Rheumatol. 2017;13:41–51. [DOI] [PubMed] [PMC]
Caiazzo E, Cerqua I, Riemma MA, Turiello R, Ialenti A, Schrader J, et al. Exacerbation of Allergic Airway Inflammation in Mice Lacking ECTO-5’-Nucleotidase (CD73).Front Pharmacol. 2020;11:589343. [DOI] [PubMed] [PMC]
Schneider E, Rissiek A, Winzer R, Puig B, Rissiek B, Haag F, et al. Generation and Function of Non-cell-bound CD73 in Inflammation.Front Immunol. 2019;10:1729. [DOI] [PubMed] [PMC]
Heuts DP, Weissenborn MJ, Olkhov RV, Shaw AM, Gummadova J, Levy C, et al. Crystal structure of a soluble form of human CD73 with ecto-5’-nucleotidase activity.Chembiochem. 2012;13:2384–91. [DOI] [PubMed]
Airas L, Niemelä J, Salmi M, Puurunen T, Smith DJ, Jalkanen S. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells.J Cell Biol. 1997;136:421–31. [DOI] [PubMed] [PMC]
Maksimow M, Kyhälä L, Nieminen A, Kylänpää L, Aalto K, Elima K, et al. Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis*.Crit Care Med. 2014;42:2556–64. [DOI] [PubMed]
Doherty GA, Bai A, Hanidziar D, Longhi MS, Lawlor GO, Putheti P, et al. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease.Eur J Immunol. 2012;42:3062–72. [DOI] [PubMed] [PMC]
